UTTAR PRADESH JOURNAL OF ZOOLOGY

42(18): 52-63, 2021
ISSN: 0256-971X (P)

POTENTIAL INHIBITORS AGAINST SARS-COV-2 BY TARGETING PROTEINS RESPONSIBLE FOR ENVELOPE FORMATION AND VIRION ASSEMBLY

ZEBA KHATOON[1] AND ANAMIKA CHAUDHARY[1*]

[1]Department of Biotechnology, Noida International University, Greater Noida (U. P.) India.

AUTHORS' CONTRIBUTIONS

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

Editor(s):
(1) Dr. Juan Carlos Troiano, Professor, University of Buenos Aires, Argentina.
(2) Dr. Ana Cláudia Correia Coelho, University of Trás-os-Montes and Alto Douro, Portugal.
Reviewers:
(1) Yogita Gupt, India.
(2) Muhamad R. Abdel Hameed, Assiut University, Egypt.
(3) Qingliang Shen, Ferring Research Institute, USA.
(4) Kabbale Fredrick George, Makerere University, Uganda.
(5) Kasamba Ilunga Eric, Université de Lubumbashi, Republic of the Congo.

Received: 25 June 2021
Accepted: 11 August 2021
Published: 06 September 2021

Review Article

ABSTRACT

Even though extreme research there is presently no efficient vaccine accessible against the new-found severe acute respiratory syndrome coronavirus-2 causing COVID-19 pandemic. The clinical administration of COVID-19 has been restricted to infection prevention along with control measures linked with supportive care. In the meantime, efforts to achieve a successful therapy to prevent virus replication, alleviate the symptoms, increase survivability as well as reduce mortality are ongoing. In this review, we found that a drug named Tipranavir (used in more than top 20 drugs in different countries against Covid-19) that can be docked against the QNH88662.1 envelope protein [Severe acute respiratory syndrome coronavirus 2] and at least cease the activity so that its action of spreading infection can be prevented. Pharmacokinetics and ADME studies show that drugs need some improvement. It is slightly heavier than Lipinski rule of five criteria. We propose improvement in future aspects.

Keywords: Tipranavir; Covid-19; envelope protein; pharmacokinetics and ADME studies.

1. INTRODUCTION

The quantity of COVID-19 cases in India expanded at a moderately sluggish speed after the main case was recorded on January 31, 2020. Every day cases topped at around 98,000 cases around September 15, declining consistently for a very long time from that point. A month into 2021, it appeared to be conceivable that India's experience would be not normal for those of the US or Brazil, the two of which

**Corresponding author: Email: anamika.chaudhary@niu.edu.in;*

saw numerous influxes of the infection and recorded numerous passing inside the previous year.

Coronavirus is brought about by the SARS-CoV-2 infection, an individual from the COVID-19 family. Viruses have been alluded to as a "piece of terrible news enveloped with a protein" by the scholars Jean and Peter Medawar. This expression portrays both the shell of protein particles that ensures the hereditary material of the infection, just as the hereditary material, for this situation a solitary RNA molecule, the "awful news". This molecule contains all the infection requires to duplicate itself once it connects to, and afterward enters, a living cell. At the point when an infection taints a living cell, the data contained in its RNA grouping is perused (or "interpreted") to make proteins. A portion of these proteins help the RNA make duplicates of itself ("replication"), others are associated with "wrapping up" the RNA, but other "bundle" this into new infection particles. The last advance in the life-pattern of the infection is for these new infection particles (or virions) to get away from the tainted cell so they can proceed to contaminate others, rehashing this interaction.

Viruses just exist to make duplicates of them. That they cause infection is really accidental to this bigger reason. In any case, these duplicates are now and then defective. On the off chance that the RNA arrangement varies by at least one letters from the first one it was replicated from, this can now and then prompt an alternate protein succession. This change can influence portions of the infection, modifying the manner in which the infection ties to the cells it taints. It can likewise intrude with the way antibodies tie to explicit uncovered pieces of the infection they were intended to perceive. A few transformations in areas that antibodies look to tie and kill the infection can make procured invulnerability less viable. Individuals can likewise get re-contaminated if antibodies melt away with time; however, the invulnerable memory of a prior experience with the infection forestalls or restricts sickness.

Freak viruses conveying generally similar arrangement of significant changes are called variations in the event that they are likewise seen to be liable for a sensible part of contaminations. Changes are generally normal, yet every transformation doesn't make a variation. Those variations which are bizarrely skilled at contaminating individuals, or which lead to more serious types of sickness, are called variations of concern (VOCs). A few variations are explicit to areas of India, including one called B.1.36, discovered to be available in a decent part of cases tried in Bengaluru. The particular transformation conveyed by the B.1.36 variation, called N440K, is far reaching in cases from the southern states. The B.1.1.7 variation presently rules new cases in Punjab.

Yet, more worryingly, ongoing research show that the L452R change is additionally equipped for invulnerable departure, evading the two antibodies produced by an earlier disease or a portion of immunization just as different types of insusceptibility that don't depend on antibodies. A different line of inquiries has to do with the resistant framework's communication with the new variations. Does an earlier disease with the first strain or a later immunization shield generously against a contamination from the new variation? Then again, could the result be more terrible?

2. LITERATURE CITED

Covid Disease 2019 (COVID-19) was announced as pandemic by the World Health Organization on March eleventh, 2020 essentially because of the speed and size of the transmission of the infection [1]. Prior to that, it began as a pandemic in territory China with the center being right off the bat announced in the city of Wuhan, Hubei area in February 26th [2-4]. The etiologic specialist of COVID-19 was detached and distinguished as a novel Covid, at first assigned as 2019-nCoV [5]. Afterward, the infection genome was sequenced [6] and in light of the fact that it was hereditarily identified with the Covid flare-up answerable for the SARS episode of 2003, the infection was named as extreme intense respiratory disorder Covid 2 (SARS-CoV-2) by the International Committee for Taxonomy of Viruses [7,8].

Taking into account that large numbers of the early patients worked in or visited the South China Seafood Market as opposed to the traded cases, it was proposed either a human to human transmission or a more boundless creature source [9]. A speculated bat cause was proposed after 96 % genome grouping character was exhibited between SARS-CoV-2 and another Covid named Bat-CoV-RaTG13 disengaged from bat species which colonized a territory almost 2000 km away from Wuhan [6,10]. Pangolins were likewise proposed as common host of Covids [11,12]. Notwithstanding, proof of human to human transmission turned out to be firmly upheld on January 22nd, 2020 after a visit directed by a WHO designation to the city of Wuhan [13]. To date in excess of 42,000 SARS-CoV-2 RNA genomes have been transferred in the Global Initiative on Sharing All Influenza Data, known as GISAID [14].

SARS-CoV-2 has a place with the beta subgrouping of the Coronaviridae family and are wrapped infection

containing a positive-sense, single-abandoned RNA with 29,891 bases of size [15,16]. The genome encodes for 29 proteins engaged with the disease, replication and virion gathering measure. Like other Covids they are described by the presence of crown-like spikes on their surface [17]. The spike S protein from SARS-CoV-2 contains a receptor restricting space (RBD) that ties the human angiotensin-changing over compound 2 (ACE2) and in this way, advances film combination and take-up of the infection into human cells by endocytosis [18,19]. The RBD present in the spike protein is the most factor area of the Covid genome [6,20]. Underlying and biochemical research have proposed that RBD from SARS-CoV-2 ties with high proclivity to ACE2 contrasted with other SARS-CoV viruses [21-23]. Notwithstanding, the human ACE2 protein inconstancy may likewise be a factor for the high restricting liking [21].

3. SARS-COV-2 INFECTION, REPLICATION AND CLINICAL IMPLICATIONS

SARS-CoV-2 can be transmitted human to human by respiratory drops, close contact with unhealthy patients, and conceivably by faecal-oral and airborne contact [24-26]. It was as of late shown that airborne transmission is profoundly harmful and addresses the predominant course to spread the illness [27]. Dominant part of SARS-CoV-2 tainted people (80 %) are asymptomatic or present gentle manifestations undoubtedly because of a decent insusceptible reaction ready to control the development of the sickness [28,29]. There is proof that these asymptomatic individuals can taint others with SARS-CoV-2 [30,31]. Hence, a few suggestions incorporate wash hands regularly, stay away from close contact, cover mouth and nose with a veil, cover hacks and sniffles, and clean and sanitize every now and again contacted surfaces day by day [32].

Upon cell contact, the infection can enter the cells twoly, either by means of endosomes or plasma film combination. In the two different ways spike proteins (S1 e S2) from SARS-CoV-2 intervene connection to the cell film by restricting to the ACE2 as the section receptor [33]. Then again, virions are taken up into endosomes, spike proteins are enacted by cathepsin L or on the other hand by transmembrane protease serine 2 (TMPRSS2) in closeness to ACE2 receptor, which starts combination of the viral film with the plasma layer. The last system is more averse to trigger an antiviral safe reaction and is more effective for viral replication [34].

Once inside the cell, viral RNA is delivered, and polyproteins are interpreted. Covid genomic RNA encodes non-structural proteins (NS), that assume a basic part in viral RNA combination, and primary proteins which are significant for new virion get together. First NS proteins 1a and 1ab are deciphered and severed by the papain-like protease (PIpro) and 3C-like protease (3CLpro) to frame practical NS proteins, for example, helicase or RNA-subordinate RNA polymerase complex (RdRp). Underlying proteins S1, S2, envelope (E), layer (M) are made an interpretation of by ribosomes bound to the endoplasmic reticulum (ER) and introduced on its surface as an arrangement of virion gathering. The nucleocapsids (N) stay in the cytoplasm and are gathered along with the genomic RNA. The virion antecedent is then shipped from the ER through the Golgi mechanical assembly to the cell surface by means of vesicles. At long last, virions are delivered from the tainted cell through exocytosis and another replication cycle starts [15,35].

Manifestations and signs related with viral pneumonia are habitually appeared by patients during the beginning of COVID-19 [36-41]. Moreover, loss of taste or smell and gastrointestinal indications like queasiness, spewing or looseness of the bowels has likewise been accounted for by contaminated patients [42-44]. At the point when extreme and non-serious patients are analyzed, conditions like hypertension, diabetes, cardiovascular and kidney sicknesses increment the danger of disease a few overlap [45].

Albeit observational research announced more established age and the presence of comorbidities as hazard factors for expanded infection seriousness in patients with COVID-19, it quickly turned out to be certain that extreme sickness can likewise happen in more youthful patients with no prior ailments [46]. Serious COVID-19 is firmly connected with hyperinflammation as confirmed by more significant levels of C-responsive protein, ferritin and D-dimers in blood just as expanded neutrophil-to-lymphocyte proportion and serum levels of a few fiery cytokines and chemokines [39,47,48,49].

Among hospitalized patients with COVID-19 entanglements like pneumonia, sepsis, respiratory disappointment, and intense respiratory misery disorder (ARD) are as often as possible found [50]. SARS-CoV-2 - incited ARDs show likenesses to that saw in other viruses and microscopic organisms contaminations [51,52]. Overproduction of supportive of provocative cytokines because of SARS-CoV-2, known as cytokine storm, prompts expanded danger of vascular porousness, organ disappointment and thusly demise if uncontrolled [53,54]. It has been

exhibited that qualities encoding for interleukins, for example, IL-1α, IL-1β, IL-6, IL-10, chemokines (CCl2, CCl3, CCL5, CCL10), and interferon (IFN-α2, IFN-β1, IFN-2) are exceptionally communicated in patients, after 24 h post disease with SARS-CoV-2, and this is related with expanded penetration of T cells, NK cells and monocytes [55,56]. This perception is like what was accounted for other Covids contaminations, for example, Middle East respiratory disorder (MERS) brought about by MERS-CoV, where interleukins (IL-6, IL-23α, IL-10, IL-7, IL-1α, IL1β) and interferon (IFN-α2, IFN2, IFN-γ) have expanded significantly in a time of 24 h post disease [57]. Moreover, ensuing development after 24 h of 463 seriously tainted COVID-19 patients showed diminished number of all out lymphocytes, CD3+, CD4+, and CD8 + T lymphocytes, which could be the factor bringing about deadly pneumonia [55]. Expanded groupings of IL-15, IL-17 and TNF-α additionally has been accounted for MERS-CoV diseases [58].

Interleukin 17A (IL-17A) is an individual from a multifunctional cytokine family that has demonstrated to be a vital driver in constant tissue irritation, particularly in joint and skin like psoriasis, psoriatic joint pain and ankylosing spondylitis [59,60]. The part of IL-17A can be defensive, in guard from both extracellular microorganisms and viruses that contaminate aviation route mucous layers or can prompt hyper-irritation. Besides, its job is by all accounts subject to which tissue it is communicated (gut, lung or skin) [61]. IL-17A is chiefly delivered by Th17 cells, yet additionally by intrinsic and other versatile invulnerable cell parts, for example, regular executioner T cells, macrophages, neutrophils, CD8 + T cells, γδ T cells and inborn lymphoid cells [62]. IL-17A is known to animate the creation of IL-8, monocyte chemoattractant protein-1 (MCP-1) and development controlled oncogene-α (Gro-α), which increment the enlistment of neutrophils and monocytes; it additionally invigorates the creation of IL-6 because of extracellular microorganisms; and furthermore, granulocyte-settlement animating variable (G-CSF) and granulocyte-macrophage (GM)-CSF, which thusly, animate the extension of myeloid heredities and the creation of different middle people, for example, IL-1, TNF-α and Prostaglandin E2 (PGE2) [63]. It has been as of late shown that fringe mononuclear platelets from patients with serious COVID-19 disease introduced strikingly high quantities of coursing Th17 cells, corresponding with expanded degrees of cytokines including IL-1β, IL-2, IL-7, IL-10, IL-17, G-CSF, interferon γ-prompted protein 10 (IP-10), MCP-1, macrophage provocative proteins (MIPs) and TNF-α. Because of the job of IL-17A in tissue aggravation and its putative defensive capacity, IL-17A has been considered as new helpful objective for the treatment or potentially the board of COVID-19 [64-66]. Moreover, to confront this commonplace cytokine storm, it was recommended that the medication fedratinib, a Janus kinase 2 (JAK2) little particle inhibitor could be a potential remedial specialist utilized for COVID-19 patients with this expanded Th17 profile [67]. Consequently, one of the treatment methodologies for COVID-19 incorporates anticytokine treatments or immunomodulators to target overactive cytokine reaction [68].

Other than IFN type 1 and IFN type 2, a third kind of interferon family, named lambda (IFN-λ), was recognized. Indeed, this family comprises of four individuals in people: IFN-λ1/IL-29, IFN-λ2/IL-28A, IFN-λ3/IL-28B, and IFN-λ4. They share low homology with type I IFNs and IL-10 and show intense antiviral action [69]. IFN-λ act by restricting to a heterodimeric IFN-λ receptor (IFNLR) unpredictable, initiating a STAT phosphorylation-subordinate flagging course and in this way inciting a few qualities that tweak resistance through a complex forward and criticism circles [70]. It has been shown that IFN-λ are incited at lower viral weight in flu infection contaminations and before type I IFNs. This is viewed as a system to restrict the underlying disease by instigating viral protection from cells and assisting them with managing the infection load [71]. Additionally, IFN-λ appears to do not have the solid favorable to provocative impacts of type I IFNs and are somewhat tissue-defensive and mitigating and thusly has been proposed as a possible system for the treatment of COVID-19 patients to assist with two principle clinical issues: industrious infection presence in the lung and enlistment of a "cytokine storm" [72]. In this manner, prophylactic portion heparin has been suggested for hospitalized patients [73].

It is feasible to distinguish fundamentally three phases or stages in the regular history of COVID-19 and the main stage is identified with the beginning of the infection and for the most part portrayed by the improvement of flu like side effects from gentle to direct [36,74]. In this stage, it is feasible to identify pneumonia-like indications proved as lung opacities as found in chest radiography or as glass opacities in figured tomography (CT) [75,76]. Coronavirus pneumonia presents especially particular highlights, for example, extreme hypoxemia regularly connected with close to ordinary respiratory framework consistence with variable levels of seriousness [77]. Contingent upon the seriousness of stage 2 patients can improve or deteriorate with the need of intubation and ventilation. These patients are average instances

of the stage 3 which is portrayed by hyperinflammation and sepsis of lungs and patient frequently requires emergency unit and the greater part of them sadly can not defeat the contamination.

Proteins engaged with the SARS-CoV-2 passage and replication component into have cell have been the fundamental focuses for drug testing and advancement. As referenced before Covids are made by nonstructural proteins (NS) and underlying proteins (S). Truth be told, the SARS-CoV-2 RNA genome comprises of eleven open understanding casings (ORFs), arranged in the accompanying request: ORF1ab, ORF2 (Spike protein), ORF3a, ORF4 (Envelope protein), ORF5 (Membrane protein), ORF6, ORF7a, ORF7b, ORF8, ORF9 (Nucleocapsid protein), and ORF10 in the 5' to 3' heading. The ORF1a/b codes for a polyprotein (PP1a and PP1ab), which includes 16 nonstructural proteins (NSPs) [81]. NSP1, known as Leader protein, ties to 40S ribosome from have cell to inactivate have mRNA interpretation by corruption, while keeps viral RNA flawless [79,82]. NSP2, a monitored protein in SARS-CoV-1, was appeared to tie two host proteins: prohibitin 1 and prohibitin 2 (PHB1 and PHB2) engaged with cell cycle movement, cell relocation, cell separation, apoptosis, and mitochondrial biogenesis [80,83]. NSP3 is a huge papain-like proteinase with around 200 kDa in size, whose grouping contains a few rationed spaces including ssRNA restricting, ADPr restricting, G-quadruplex restricting, protease (papain-like protease), and NSP4 restricting areas other than a transmembrane space [81]. The papain like protease area is liable for the arrival of NSP1, NSP2, and NSP3 from the N-terminal locale of polyproteins 1a and 1ab from Covids and in this manner is viewed as a significant objective for antiviral specialists [82]. NSP4 is a protein that communicates with NSP3 which is fundamental for viral replication. It contains a transmembrane area and conceivably cooperates with have proteins with a component of layer adjustment in SARS-CoV-1 [83]. NSP5 is a 3C-like proteinase (3CLpro) with homology to the Middle East Respiratory Syndrome (MERS) Covid protease.

This protease can divide at eleven unique locales to yield develop and transitional nonstructural proteins [84]. NSP6 is believed to be engaged with the age of autophagosomes from the endoplasmic reticulum dependent on research with avian Covid NSP6, which work with get together of replicase proteins and stay away from debasement of viral segments [85]. NSP7 structure a complex with NSP8 and NSP12 proteins to create a functioning RNA polymerase [86]. In light of studies with porcine conceptive and respiratory disorder infection (PRRSV), NSP9 has been appeared to connect with the DEAD-box RNA helicase 5 (DDX5) cell protein, a significant relationship for viral replication [87]. NSP10 associates with NSP14 bringing about the incitement of the action of this last protein, what work as a S-adenosylmethionine (SAM)- subordinate (guanine-N7) methyl transferase (N7-MTase) [88]. NSP10 likewise interfaces with NSP16, a 2′-O-methyltransferase, whose action is invigorated as aftereffect of this collaboration [89]. NSP11 is a little protein with 13 amino acids that has an obscure capacity. Its initial nine amino acids are indistinguishable from the initial nine amino acids of NSP12 protein. This last protein is a RNA-subordinate RNA polymerase (RdRp) that makes duplicates of the viral RNA. NSP12 structures a complex with NSP7-NSP8 fundamental for its action [90]. NSP13 fills in as a helicase that appears to collaborate with NSP12 and have 5′-triphosphatase movement also. This movement is imperative to present 5′-terminal cap of the viral mRNA during its preparing [91] along with NSP14, which has 3′-5′ exoribonuclease action and N7-methyltransferase action [92]. NSP15 has been portrayed as an endoribonuclease that separates RNA at explicit locales [93]. NSP15 proteins forestall the host invulnerable detecting framework from recognizing the infection by debasing viral polyuridine successions [94]. NSP16 is a 2′-O-Ribose-Methyltransferase that methylates the 2′-hydroxy gathering of adenines during viral RNA handling by utilizing S-adenosylmethionine as the methyl source [95].

The spike glycoprotein S is a fundamental objective of procedures utilizing killing antibodies since SARS-CoV-2 uses this protein to tie to its receptor to intercede film combination and infection passage. Protein S has a trimeric structure with every monomer comprising of two subunits, named S1 and S2, that together record for a sub-moleculeic load of roughly 180 kDa [96]. It was shown that SARS-CoV-2 S protein is less steady than SARS-CoV-1, another Covid answerable for SARS, and antibodies against SARS-CoV-1 S1 protein can restrain SARS-CoV-1 section yet not SARS-CoV-2. Additionally, sera from recuperated SARS and COVID-19 patients showed restricted cross-balance proposing that a potential recuperation from one disease may not ensure against other [96]. Curiously, the S protein of SARS-COV-2 was appeared to have a furin cleavage site which is inadequate in the S protein of SARS-COV-1 [22]. This could be one of the clarifications for the distinction in pathogenicity of these two viruses [78]. Other than spike (S) protein, nucleocapsid (N), envelope (E) and layer (M) proteins, just as 3CL protease (3CLpro), papain like protease and RNA-subordinate RNA polymerase complex (RdRp)

proteins which incorporate the helicase protein have been proposed to be antiviral targets [97].

As of late Gordon et al. [98] detailed a fascinating way to deal with attempt to discover new druggable focuses for treatment of COVID-19. A comparable methodology dependent on virtual screening was utilized to recognize potential medications that tight spot explicitly to SARS-CoV-2 3-C like protease (3CLpro), fundamental for infection replication. Three-dimensional model of the protease utilizing precious stone design of the great comparable protease ortholog SARS-CoV was arranged and uncovered 16 possibility for assessment including two repurposed medications, for example, velpatasvir and ledispavir [99].

As of February 21, 2020, a sum of 76,288 affirmed instances of Covid sickness 2019 and 2,345 passings have been accounted for in territory China [100]. Researchers are trying to discover medications to treat this infection. Antivirals including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol have been remembered for the most recent variant of the Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-actuated Pneumonia gave by the National Health Commission (NHC) of the People's Republic of China for provisional treatment of COVID-19 [101]. The fifth version of the Guidelines suggests antivirals including IFN-α, lopinavir/ritonavir, and ribavirin for treatment of COVID-19 [103]. Chloroquine phosphate and arbidol are remembered for the 6th release of the Guidelines dependent on the primer results of clinical research [102].

IFN-α is an expansive range antiviral and it is accounted for to repress SARS-CoV multiplication in vitro [104]. Lopinavir/ritonavir is a drug for the human immunodeficiency infection (HIV) utilized in mix with different prescriptions to treat grown-ups and youngsters more than 14 days old enough who are contaminated with HIV-1 [105]. Chu et al. discovered that lopinavir/ritonavir has against SARS-CoV action in vitro and in clinical research [106]. An investigation contrasted 111 patients and extreme intense respiratory disorder (SARS) treated with ribavirin monotherapy and 41 patients with SARS treated with lopinavir/ritonavir and ribavirin; patients treated with the joined treatment had a lower hazard of intense respiratory trouble condition (ARDS) and passing [106]. Chloroquine is a generally utilized antimalarial that was discovered to be a potential wide range antiviral in 2006 [107]. Chloroquine was found to impede SARS-CoV-2 contamination at lowmicromolar focus, with a half-maximal viable fixation (EC50) of 1.13 μM and a half-cytotoxic fixation (CC50) more noteworthy than 100 μM [108].

An research has uncovered that arbidol can successfully repress SARS-CoV-2 disease at a centralization of 10-30 μM in vitro [109]. Favipiravir was endorsed for treatment of novel flu on February 15, 2020 in China. Favipiravir is another kind of RNA-subordinate RNA polymerase (RdRp) inhibitor. Notwithstanding its enemy of flu infection action, favipiravir is fit for hindering the replication of flavi-, alpha-, filo-, bunya-, field, noro-and other RNA viruses [110]. Favipiravir is changed over into a functioning phosphoribosylated structure (favipiravir-RTP) in cells and is perceived as a substrate by viral RNA polymerase, hence hindering RNA polymerase action [111]. The fundamental outcomes from a sum of 80 patients (counting the test bunch and the benchmark group) demonstrated that favipiravir had more powerful antiviral activity than that of lopinavir/ritonavir [112].

Remdesivir is another possible medication for treatment of COVID-19. Creature tests [113] showed that remdesivir can adequately diminish the viral burden in lung tissue of mice contaminated with MERSCoV, improve lung work, and reduce neurotic harm to lung tissue. Wang et al. discovered that remdesivir powerfully impedes SARS-CoV-2 contamination at lowmicromolar fixations and has a high selectivity list [108]. Holshue et al. revealed that remdesivir yielded promising outcomes in the treatment of a patient with COVID-19 in the United States [114]. To assess the adequacy and wellbeing of the medication in patients with COVID-19, a randomized, fake treatment controlled, twofold visually impaired, multicenter, stage III clinical preliminary was dispatched on February 5, 2020 in China [115,116]. Patients in the test bunch got an underlying portion of 200 mg of remdesivir and an ensuing portion of 100 mg for 9 continuous days by means of intravenous mixture notwithstanding routine treatment. Patients in the benchmark group got standard treatment and a similar portion of a fake treatment. The preliminary is required to finish up before the finish of April 2020.

Cell tests demonstrated that darunavir altogether repressed viral replication at a centralization of 300 μM in vitro and that its restraint proficiency was 280-overlay that in the untreated gathering [109]. Other potential medications incorporate sort II transmembrane serine protease (TMSPSS2) inhibitors and BCR-ABL kinase inhibitor imatinib. Hoffmann et al. shown that SARS-CoV-2 uses the SARS-CoV receptor, ACE2, and the cell protease TMPRSS2 to enter target cells. A TMPRSS2 inhibitor would hinder

section and, in this manner, comprise a treatment alternative [117]. Imatinib has anticoronal movement principally on the grounds that it hinders the combination of virions with the endosomal layer [118].

4. CONCLUSION

An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homopentameric cation channel that is important for virus pathogenicity. In lipid bilayers that mimic the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane, ETM forms a five-helix bundle surrounding a narrow pore. The protein deviates from the ideal α-helical geometry due to three phenylalanine residues, which stack within each helix and between helices. Together with valine and leucine interdigitation, these cause a dehydrated pore compared with the viroporins of influenza viruses and HIV. Hexamethylene amiloride binds the polar amino-terminal lumen, whereas acidic pH affects the carboxy-terminal conformation. Thus, the N- and C-terminal halves of this bipartite channel may interact with other viral and host proteins semi-independently. The structure sets the stage for designing E inhibitors as antiviral drugs.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization.
   Available:https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---12-march-2020
   (Accessed May 16, 2020).
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382(8): 727–733.
   DOI: 10.1056/NEJMoa2001017
3. Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 health care workers in China. N. Engl. J. Med; 2020.
   DOI: 10.1056/NEJMc2005696
   Advance online publication.
4. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect. Dis. 2020;S1473-3099(20):30243-7.
   Doi: 10.1016/S1473-3099(20)30243-7
   Epub ahead of print. Erratum in: Lancet Infect Dis. (2020) Apr 15; Erratum in: Lancet Infect Dis. 2020; PMID: 32240634; PMCID: PMC7158570.
5. Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2): 135.
   DOI: 10.3390/v12020135
6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   DOI: 10.1038/s41586-020-2012-7.
7. World Health Organization. Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It; 2020.
   Available:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance
8. Virological.org. Novel Coronavirus Genome; 2019.
   Available:http://virological.org/t/issues-with-sars-cov-2-sequencing-data/473
   (Accessed 16 May, 2020).
9. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020;382(13): 1199–1207.
   DOI: 10.1056/NEJMoa2001316
10. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat. Med. 2020;26(4):450–452.
    DOI: 10.1038/s41591-020-0820-9
11. Liu P, Jiang JZ, Wan X, Hua Y, Li L, Zhou J, et al. Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? PLoS Pathog. 2020;16(5).
    DOI: 10.1371/journal.ppat.1008421
12. Zhang T, Wu Q, Zhang Z. Pangolin Homology Associated With 2019-nCoV bioRxiv; 2020.
13. World Health Organization. Mission summary: WHO Field Visit to Wuhan, China; 2020.
    Available:https://www.who.int/china/news/detail/22-01-2020-field-visit-wuhan-china-jan-2020 20-21 January
    (Accessed May 16, 2020)
14. Global Initiative on Sharing All Influenza Data. 27,000 Viral Genomic Sequences of hCoV-19 Shared with Unprecedented Speed Via GISAID; 2020.
    Available:https://www.gisaid.org/
15. Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92(4):418–423.
    DOI: 10.1002/jmv.25681

16. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol. 2020;79:104212.
DOI: 10.1016/j.meegid.2020.104212
17. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol. J. 2019;16(69):1–22.
DOI: 10.1186/s12985-019-1182-0
18. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448.
DOI: 10.1126/science. abb2762
19. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11(1):1620.
DOI: 10.1038/s41467-020-15562-9
20. Wu F, Zhao S, Yu B, Chen YM. Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
DOI: 10.1038/s41586-020-2008-3
21. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020;94(7).
DOI: 10.1128/JVI.00127-20. e00127-20
22. Walls AC, Park YP, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;180:281–292.
DOI: 10.1016/j.cell.2020.02.058
23. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367: 1260–1263.
24. Hindson J. COVID-19: faecal–oral transmission? Nat. Rev. Gastroenterol. Hepatol. 2020;17:259.
DOI: 10.1038/s41575-020-0295-7
25. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New Engl. J. Med. 2020;382(16):1564–1567.
DOI: 10.1056/NEJMc2004973
26. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 2020;26(4): 502–505.
DOI: 10.1038/s41591-020-0817-4
27. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc. Natl. Acad. Sci. U. S. A. 2020; 202009637.
DOI: 10.1073/pnas.2009637117
28. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 2014;59(1–3):118–128.
DOI: 10.1007/s12026-014-8534-z
29. Nelemans T, Kikkert M. Viral innate immune evasion and the pathogenesis of emerging rna virus viruses. Viruses. 2019;11(10):961.
DOI: 10.3390/v11100961
30. Aguirre-Duarte N. Can people with asymptomatic or pre-symptomatic COVID-19 infect others: A systematic review of primary data. medRxiv; 2020.
DOI: 10.1101/2020.04.08.20054023
31. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic viruses with COVID-19 screened among close contacts in Nanjing, China. Sci. China Life Sci. 2020;63(5):706–711.
32. Center for Disease Control; 2020. Protect.
Available:https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html
33. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2): 271–280.
34. Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology. 2018;517:9–15.
35. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14(8):523–534.
36. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 2020;395(10223):514–523.
37. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223): 507–513.

38. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720.
39. Huang C, Wang Y, Li X, Ren L. Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
40. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020;382(13): 1199–1207.
41. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J. Infect. 2020;80(4):401–406.
42. Paderno A, Schreiber A, Grammatica A, Raffetti E, Tomasoni M, Gualtieri T, et al. Smell and taste alterations in Covid-19: a cross-sectional analysis of different cohorts. Int. Forum Allergy Rhinol; 2020.
DOI: 10.1002/alr.22610
43. Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: A highly prevalent symptom of COVID-19 with public health significance. Otolaryngol. Head. Neck Surg; 2020.
DOI: 10.1177/0194599820926464. 194599820926464
44. Yan CH, Faraji F, Prajapati DP, Boone CE, De Conde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int. Forum Allergy Rhinol; 2020.
DOI: 10.1002/alr.22579
45. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95.
DOI: 10.1016/j.ijid.2020.03.017
46. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol; 2020.
DOI: 10.1038/s41577-020-0331-4
47. Yang X, Yu Y, Xu J, Shu H, Xia JA, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8(5):475–481.
48. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5): 2620–2629.
49. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis; 2020.
DOI: 10.1093/cid/ciaa248
50. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
51. Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 2008;4.
DOI: 10.1371/journal.ppat.1000115
52. D'Elia RV, Harrison K., Oyston PC, Lukaszewski RA, Clark GC. Targeting the cytokine storm for therapeutic benefit. Clin. Vaccine Immunol. 2013;20(3): 319–327.
53. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest. 1995;108:1303–1314.
54. Bouros D, Alexandrakis MG, Antoniou KM, Agouridakis P, Pneumatikos I., Anevlavis S, Pataka A, et al. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm. Med. 2004;4:6.
DOI: 10.1186/1471-2466-4-6
55. Yao Z, Zheng Z, Wu K, Junhua Z. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. Aging (Albany NY) 2020;12(9):7639–7651.
DOI: 10.18632/aging.103101
56. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect. 2020;9(1): 761–770.
DOI: 10.1080/22221751.2020.1747363
57. Wong CK, Lam CW, Wu AK. Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95–103.
DOI: 10.1111/j.1365-2249.2004.02415. x
58. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-

inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13.
DOI: 10.1016/j.cyto.2018.01.025

59. Durham LE, Kirkham BW, Taams LS. Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 2015;17:55.
60. Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin17A in spondyloarthritis. Arthritis Res. Ther. 2017;19:51.
61. Pacha O, Sallman MA, Evans SE. COVID-19: A case for inhibiting IL-17? Nat. Rev. Immunol. 2020;20:345–346.
DOI: 10.1038/s41577-020-0328-z
62. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol; 2020.
DOI: 10.1002/jmv.25770
63. D'Acquisto F, Maione F, Pederzoli-Ribeil M. From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? Biochem. Pharmacol. 2010;79:525–534.
DOI: 10.1016/j.bcp.2009.09.015
64. Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, Maione F. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? Pharmacol. Res. 2020;156:104791.
DOI: 10.1016/j.phrs.2020.104791
65. Raucci F, Mansour AA, Casillo GM, Saviano A, Caso F, Scarpa R, et al. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms. Autoimmun. Rev. 2020;19(7):102572.
DOI: 10.1016/j.autrev.2020.102572
66. Ceccarelli G, Nardi K, Marchesani F. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?" Pharmacol. Res. 2020;158:104933.
DOI: 10.1016/j.phrs.2020.104933
67. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J. Microbiol. Immunol. Infect; 2020.
DOI: 10.1016/j.jmii.2020.03.005
68. Jose RJ, Manuel A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. Lancet Respir. Med. 2020; 20.
DOI: 10.1016/S2213-2600(20)30216-2. S2213-2600
69. Andreakos E, Zanoni I, Galani IE. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control. Curr. Opin. Immunol. 2019; 56:67–75.
70. Syedbasha M, Egli A. Interferon lambda: Modulating immunity in infectious diseases. Front. Immunol. 2017;8:119.
DOI: 10.3389/fimmu.2017.00119
71. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, et al. Interferon-lambda mediates nonredundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity. 2017;46:875–890. e6.
72. Andreakos E, Tsiodras S. COVID-19: Lambda interferon against viral load and hyperinflammation. EMBO Mol. Med. 2020; 12(6):e12465.
DOI: 10.15252/emmm.202012465
73. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;1–6.
74. Kong W, Li Y, Peng M, Kong D, Yang X, Wang L, Liu M. SARS-CoV-2 detection in patients with influenza-like illness. Nat. Microbiol. 2020;5:675–678.
DOI: 10.1038/s41564-020-0713-1
75. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) viruses from Wuhan, China: key points for the radiologist. Radiology; 2020.
DOI: 10.1148/radiol.2020200241
76. Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. AJR Am. J. Roentgenol. 2020;5:1–8.
DOI: 10.2214/AJR.20.22975
77. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med; 2020.
DOI: 10.1007/s00134-020-06033-2
78. Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020;39:198–216.
DOI: 10.1007/s10930-020-09901-4
79. Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL, Makino S. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of

mRNAs: Viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011;7. DOI: 10.1371/journal.ppat.1002433

80. Cornillez-Ty CT, Liao L, Yates JR, Kuhn P, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling. J. Virol. 2009;83:10314–10318.
81. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antiviral Res. 2018;149:58–74.
82. Baez-Santos YM, St. John SE, Mesecar AD. The SARS coronavirus papain-like protease: structure, function, and inhibition by designed antiviral compounds. Antiviral Res. 2015;115: 21–38.
83. Sakai Y, Kawachi K., Terada Y, Omori H, Matsura Y, Kamitani W. Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication. Virology. 2017;510:165–174.
84. Tomar S, Johnston ML, St. John SE, Osswald HL, Nyalapatla PR, Paul LN, et al. Ligand induced dimerization of middle east respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro) implications for nsp5 Regulation and the Development of Antivirals. J. Biol. Chem. 2015;290:19403–19422.
85. Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy. 2014;10:1426–1441.
86. Te Velthuis AJ, van de Worm SH, Snijder E. The SARScoronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res. 2012;40:1737–1747.
87. Zhao S, Ge X, Wang X, Liu A, Guo X., Zhou L, Yu K, Yang H. The DEAD-box RNA helicase 5 positively regulates the replication of porcine reproductive and respiratory syndrome virus by interacting with viral Nsp9 in vitro. Virus Res. 2015;195:217–224.
88. Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y, et al. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc. Natl. Acad. Sci. U. S. A. 2015;112:9436–9441.
89. Wang Y, Sun Y, Wu A, Xu S, Pan R, Zeng C, et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide *in vitro* and *in vivo* to reduce replication and pathogenesis. J. Virol. 2015; 89:8416–8427.
90. Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE, Decroly E, et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc. Natl. Acad. Sci. U. S. A. 2014;111:E3900–E3909.
91. Ivanov KA, Thiel V, Dobbe JC, van der Meer Y, Snijder EJ, Ziebuhr J. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J. Virol. 2004;78:5619–5632.
92. Case JB, Ashbrook AW, Dermody TS, Denison MR. Mutagenesis of S-adenosyl-l-methionine-binding residues in coronavirus nsp14 N7-methyltransferase demonstrates differing requirements for genome translation and resistance to innate immunity. J. Virol. 2016; 90:7248–7256.
93. Bhardwaj K, Sun J, Holzenburg A, Guarino LA, Kao CC. RNA recognition and cleavage by the SARS coronavirus endoribonuclease. J. Mol. Biol. 2006;361:243–256.
94. Hackbart M, Deng X, Baker S. C Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc. Natl. Acad. Sci. U. S. A. 2020;117:8094–8103.
95. Decroly E, Debarnot C, Ferron F, Bouvet M, Coutard B, Imbert I, et al. Crystal structure and functional analysis of the sars-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex. PLoS Pathog. 2011;7
96. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11(1):1620. DOI: 10.1038/s41467-020-15562-9
97. Calligari P, Bobone S, Ricci G, Bocedi A. Molecular investigation of SARS-CoV-2 proteins and their interactions with antiviral drugs. Viruses. 2020;12:445.
98. Gordon DE, Jang GM, Bouhaddou M, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature; 2020. DOI: 10.1038/s41586-020-2286-9
99. Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129. DOI: 10.12688/f1000research.22457.2
100. Update on the prevalence and control of novel coronavirus-induced pneumonia as of 24:00 on February 21.

Available:http://www.nhc.gov.cn/xcs/yqtb/202002/543cc508978a48d2b9322bdc83daa6fd.shtml
(Accessed February 23,2020). (in Chinese).

101. Shanghai Institute of Materia Medica website, Chinese Academy of Sciences. A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University discover a group of old and traditional Chinese medicines that may be efficacious in treating the novel form of pneumonia.
Available:http://www.simm.ac.cn/xwzx/kydt/202001/t20200125_5494417.html
(Accessed February 22, 2020). (in Chinese).
102. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 6th ed.
Available:http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf
(Accessed February 23, 2020). (in Chinese).
103. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 5th ed.
Available:http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf
(Accessed February 18, 2020). (in Chinese).
104. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006;3:e343.
105. Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, Liu A, et al. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1- infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol. 2019;10:1472.
106. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59:252-256.
107. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67-69.
108. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. Cell Res; 2020.
109. News: Abidol and darunavir can effectively inhibit coronavirus.
Available:http://www.sd.chinanews.com/2/2020/0205/70145.html
(Accessed February 21, 2020). (in Chinese).
110. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85-94.
111. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 2017;93:449-463.
112. Available:http://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1-867a-d5524bc59cd6.html
(Accessed February 22, 2020). (in Chinese).
113. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERSCoV. Nat Commun. 2020;11:222.
114. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med; 2020.
115. Mild/Moderate 2019-nCoV Remdesivir RCT.
Available:https://clinicaltrials.gov/ct2/show/NCT04252664 (accessed February 22, 2020). (in Chinese).
116. Severe 2019-nCoV Remdesivir RCT.
Available:https://clinicaltrials.gov/ct2/show/NCT04257656
(Accessed February 22, 2020). (in Chinese).
117. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv.
DOI: 2020.2020.2001.2031.929042
118. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016; 90:8924-8933.